Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

Background: Clinical trials for antiparkinsonian drugs aimed at managing motor complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into “troublesome” and “non-troublesome” categories. Yet, given the choice, most patients would prefer to live without experiencing...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Walsh, Ryan R., Pahwa, Rajesh, Chernick, Dustin, Formella, Andrea E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032973/
https://www.ncbi.nlm.nih.gov/pubmed/33841311
http://dx.doi.org/10.3389/fneur.2021.645706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032973/
https://www.ncbi.nlm.nih.gov/pubmed/33841311
http://dx.doi.org/10.3389/fneur.2021.645706

Ejemplares similares